Divvying Up The Stem Cell Bonanza
By Business Week,
Business Week
| 11. 22. 2004
California's Proposition 71 has critics of conflicts and favoritism ready to pounce
Long before California voters passed Proposition 71 on Nov. 2, authorizing the state to pour $3 billion of taxpayers' money into stem cell research, the measure generated plenty of debate. And it wasn't just conservatives opposing the measure on religious grounds. Even supporters of the research, which one day could lead to cures for everything from diabetes to cancer, argued that the law gives vested interests too much say over who will get the funds.
So as officials move to appoint an oversight committee that will weigh funding requests, they are mindful that critics will be watching their every move. While architects of the law insist the appropriate checks and balances are built in, controversy continues to swirl around a decision-making process that some see as overly secretive. "Clearly the initiative is written to invite every conceivable form of corruption in the allocation of these funds," says Republican State Senator Tom McClintock, who opposed the law.
The controversy in California is broadly echoed at the federal level. Over...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...